ABSTRACT -PURPOSE: Triple therapy for HCV-1 infection consists in boceprevir or telaprevir, ribavirin and PEG-interferon. Telaprevir is a P-glycoprotein substrate and it is metabolized by CYP3A4/5. No data have been published on intracellular penetration of telaprevir. We determined peripheral blood mononuclear cells (PBMCs) and trough plasma S and R telaprevir isomers concentrations; moreover, we evaluated the influence of some single nucleotide polymorphisms (SNPs) on these pharmacokinetic data after 1 month of triple therapy in humans. METHODS: Plasma and intracellular telaprevir concentrations were determined at the end of dosing interval (Ctrough) using ULPC-MS/MS validated methods; allelic discrimination was performed through real-time PCR. RESULTS: Median telaprevir Ctrough plasma concentrations were 2579 ng/mL and 2233 ng/mL for the pharmacologically more active S, and R, enantiomers, respectively, with median S/R plasma ratio of 1.11. In PBMC, the medians were 6863 ng/mL and 1096 ng/mL for S and R, respectively, with median S/R being 5.73. The PBMC:plasma ratio for S was 2.59 for R. Plasma ribavirin concentrations were directly correlated with plasma S-telaprevir concentrations. In linear regression analysis, only CYP24A1_rs2585428 SNP (p=0.003) and body mass index (p=0.038) were able to predict S-telaprevir PBMC concentrations. CONCLUSIONS: Our preliminary data could increase the understanding of mechanisms underlying telaprevir intracellular and plasma exposure, suggesting the implementation of pharmacogenetics in these drug kinetic studies.
INTRODUCTION
For many years, "dual therapy" with pegylated (PEG) interferon α (IFNα) and ribavirin (RBV) was considered the standard treatment. The role of this drug consists in a host immunomodulation and in an indirect antiviral effect, since they do not target HCV genome or proteins (1) . In 2011the first direct-acting antivirals, boceprevir (BOC) and telaprevir (TLV) were approved by the United States Food and Drug Administration for use as "triple therapy" in combination with PEG-IFNα/RBV in patient affected by HCV-1(2). Both these direct-acting antivirals act on HCV NS3/4A protease and show two different isomeric forms (3, 4) .
The main limitation of these treatments was the increase of some already known adverse events of double therapy, such as hemolytic anemia (5) (6) (7) .This increased toxicity seems to be due to increased renal impairment risk by TLV, leading to reduced RBV elimination, thus elevated intracellular concentration, thereby, hemolysis (8, 9) . RBV, and other anti-HCV drugs, target on hepatocytes, but monitoring liver drug concentration is difficult due to biopsies feasibility; for this reason, the most easy-to-reach peripheral blood mononuclear cells (PBMCs) could be a valid "surrogate" to investigate intracellular drug concentrations (10) (11) (12) (13) .
Our group study showed that TLV plasma Ctrough levels were influenced by ATP-binding cassette (ABC) B1and B11 SNPs, with a potential influence on intracellular levels being the involvement of P-glycoprotein (14) .
The aims of this retrospective study carried out after 1 month exposure to triple therapy of a cohort of HCV-1 genotype infected patients were to, first, determine TLV in plasma and, for the first time, in PBMCs, and second, evaluate the ________________________________________ influence of single nucleotide polymorphisms (SNPs) in genes involved in RBV (15) and in TLV transport, also SNPs of vitamin D pathway, and their correlation with intracellular TLV.
METHODS

Characteristics of the study population
Chronic hepatitis C affected patients treated with PEG-IFNα 2a (180mg/week) plus RBV (15mg/Kg/day) for 4 weeks followed by TLV (1125mg/12h) enrolled at Amedeo di Savoia Hospital (Turin, Italy) between 2012 and 2014 were enrolled. Inclusion criteria were: HCV-1 genotype patients without major contraindication to IFNα, RBV and TLV therapy, 18 years old, no co-infection, no concomitant interacting drugs, no IFN, RBV and TLV modification up to week 4 of triple therapy and no concomitant vitamin D administration. Drop-out patients for any reason were excluded from this analysis.
Study protocol "HCV-GEN" was approved by the local Ethics Committee. A written informed consent for the study was obtained from each enrolled subject.
Pharmacogenetics analyses
DNA was extracted from blood using the QIAamp DNA Mini Kit (Qiagen, Valencia, CA). Allelic discrimination analysis was performed using TaqMan assays (Applied Biosystems, Foster City, CA) through real-time PCR (BIORAD, Milano, Italia).
Plasma RBV and TLV concentrations measurement RBV and TLV isomers plasma levels were determined from samples obtained at the end of dosing interval (Ctrough, 12 h ± 3 h) at week 4 of triple therapy. Patient samples (collected in the lithium-heparin tube, 7 mL) were centrifuged at 1500 rpm for 10 minutes at 4° C within 30 minutes from blood sampling and plasma was stored in criovials at -20° C before the analysis. RBV concentrations were determined using a high performance liquid chromatography system coupled with an ultraviolet determination (HLPC-UV), according to a chromatographic method previously published and routinely used in our laboratory (16) .
TLV isomers concentrations were determined using a validated reverse phase ultra performance liquid chromatography tandem mass spectrometry method (ULPC-MS/MS)(4).
PBMCs TLV concentrations measurement
Intra-PBMC TLV isomers concentrations were measured through an UPLC-MS/MS coupled with On-Line Solid Phase Extraction validated method (17) . Briefly, PBMC samples were isolated by density gradient using CPT vacutainers; the resulting extracts were centrifuged and 20 µl of supernatants were directly injected into the OSM platform (Waters, Milford, MA, USA) for the SPE protocol.
The chromatographic separation was obtained on a BEH C18 1.7 um 2.1x150 mm column with a gradient of 2 mobile phases: A, water + NH4OH and B, acetonitrile:methanol 50:50 (v:v).
Statistical analyses
For descriptive statistics, continuous variables were summarized as median (IQR, interquartile range, 25th to 75th percentiles), categorical variables were described as frequency and percentage.
All 
RESULTS
Characteristics of patients
Ten patients were included in this analysis: their characteristics were collected in Table 1 .
Pharmacogenetics Analyses
All the studied SNPs were in Hardy-Weinberg equilibrium; variant allele frequencies were resumed in Table 2 . (Table 1) were observed among genetically defined groups.
Only IL28B_rs12979860 and rs8099917 SNPs resulted in complete LD (D'=1) in our population. None of the analyzed SNPs were statistically associated with TLV PBMC exposure.
Ctrough Analyses
Median TLV plasma Ctrough was 2579 ng/mL (IQR 1476-2903 ng/mL) of S and 2233 ng/mL (IQR 1288-2488 ng/mL) of R isomers. Median S/R plasma ratio was 1.11 (IQR 1.01-1.27). Median value obtained for intra-PBMCS levels was 6863 ng/mL (IQR 5383-7908 ng/mL) and 1096 ng/mL (IQR 747-1976 ng/mL) for R. Median intra-PBMCS/R ratio was 5.73 (IQR 3.68-8.10), whereas S-TLV in PBMC/plasma ratio was 2.59 (IQR 2. 29-4.30) . A significant correlation between RBV plasma concentration and plasma S-TLV (p =0.708; p=0.022), R (p =0.764; p=0.010) and S-TLV in PBMC/plasma ratio (p= -0.702; p=0.024) was found; plasma R-TLV correlated with S-TLV in PBMC/plasma ratio (p = -0.721; p=0.019). Plasma S/R was significantly correlated with S-TLV in PBMC/plasma ratio (p = -0.759; p=0.011).
In linear regression analysis, only CYP24A1_rs2585428 SNP (p=0.003; OR:-2567; IC95%:-3933--1202) and body mass index (BMI, p=0.038; OR:263; IC95%:19-507) were predictable of the intra-PBMC S levels.
DISCUSSION
TLV specifically blocks HCV polyprotein processing by covalently and reversibly binding to the active-site serine of viral NS3-4A protease (18) . It is metabolized in the liver through hydrolysis, oxidation and reduction reactions by CYP3A4. TLV predominant inactive metabolites are R-diastereomer (30-fold less active), pyrazinoic acid and a reduced α-ketoamide bond one (19) . Weiss et al. showed that this drug is a moderate inhibitor and substrate of P-glycoprotein and an strong inductor of ABCG2 (20) . TLV is eliminated in faeces (82%), expired air (9%) and urine (1%) (19) . PEG-IFNα increases TLV steady state (22%), Cmax and AUC (30-40%) (21) .
In this paper, we show, for the first time, that despite a lack stereoselectivity in plasma, intra-PBMC levels of S were about 5-fold greater than the R enatiomer. Furthermore, we confirmed the observation (22) that RBV plasma levels were directly correlated with S-TLV plasma concentrations, consequently with S-TLV in PBMC/plasma ratio following the administered fix-dose regimen. Conversely, we found that RBV is also correlated with R-isomer plasma exposure. This aspect has not yet been fully clarified, although several hypotheses have been formulated (6, 23) : probably, the glomerular filtration activity reduction, due to TLV administration, could lead to minor RBV excretion, thus its higher plasma concentrations.
In linear regression analysis, we found that BMI and a polymorphism in CYP24A1 gene were able to predict S intracellular levels. Particularly, BMI was a positive predictor factor, whereas CYP24A1 SNP was a negative one.
Many immune mechanisms have been identified for spontaneous viral clearance and for the success of antiviral therapy (24, 25) .
The activated vitamin D is an important immunomodulator and most of its biological effects are mediated through vitamin D receptor (VDR) (26) .
Polymorphisms in genes of enzymes involved in vitamin D inactivation are important for prostate cancer prognosis (27) and HCV-2/3PEG-IFNα/RBV treatment outcomes; particularly, CYP24A1_rs2585428GG positively predicts therapeutic failure and negatively early virological response (28) .
Intra-PBMCs pharmacokinetics of TLV deserve further investigation to better understand the role of intracellular drug concentrations in determining treatment efficacy and toxicity.
TLV therapeutic drug monitoring could be useful tool for the management of HCV infected patients (29) and the knowledge of intracellular penetration mechanism may be the key factor to improve treatment outcome.
Also concerning BOC, a study by our group suggested a positive and significant correlation between plasma and PBMC levels. Moreover, we revealed that plasma levels of S-BOC active isomer and a polymorphism in the vitamin D receptor were able to predict S-intracellular exposure, whereas SNPs in aldo-keto reductase 1, breast cancer resistance protein1and solute carrier family 28genes predicted S-TLV in PBMC/plasma ratio (30) .
Our preliminary data could increase the understanding of mechanisms underlying TLV intracellular and plasma exposure, suggesting the implementation of pharmacogenetics in these drug kinetic studies.
Sample size is the main limitation of this study, thus these tests have to be confirmed in a wider cohort of patients. It could be useful to evaluate intracellular RBV concentration data to better understand the mechanisms underlying its interaction with TLV.
To date, in several countries, new Directacting antivirals have been approved, opening the new era of IFN-free, reducing duration and increasing success rate therapy.
A similar approach should be useful for the study of these new drugs, to promptly understand pharmacogenetic factors involved in the regulation of their plasma and intracellular pharmacokinetics.
